Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-GD2 chimeric antigen receptor T cell therapy - Bellicum Pharmaceuticals

Next Previous
X
Search
Drug Profile

Anti-GD2 chimeric antigen receptor T cell therapy - Bellicum Pharmaceuticals

Alternative Names: Anti-GD2 CAR transduced T cells - Bellicum Pharmaceuticals; Anti-GD2 CIDeCAR T cell therapy - Bellicum Pharmaceuticals; Anti-GD2 third party CAR T cell therapy - Bellicum Pharmaceuticals; GD2-CAR.OX40.28.z.ICD9

Latest Information Update: 02 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bellicum Pharmaceuticals
  • Developer National Cancer Institute (USA)
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 30 May 2022 Discontinued - Phase-I for Solid tumours (In adolescents, In children, Metastatic disease, Recurrent, Second-line therapy or greater, In adults) in USA (IV) (Takeda pipeline, June 2022)
  • 08 Apr 2022 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours(In adolescents, In children, Metastatic disease, Recurrent, Second-line therapy or greater, In adults) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top